Top Page
Inoviq Ltd
(Sydney:IIQ)
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Inoviq Ltd Business Overview & Revenue Model
Inoviq Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82M | 1.82M | 535.12K | 398.19K | 276.75K | 1.27M |
| Gross Profit | -1.56M | -1.56M | 454.11K | -1.04M | -1.88M | -2.21M |
| EBITDA | -6.16M | -6.16M | -6.34M | -9.32M | -19.39M | -6.05M |
| Net Income | -6.93M | -6.93M | -6.55M | -8.97M | -18.20M | -11.15M |
Balance Sheet | ||||||
| Total Assets | 18.46M | 18.46M | 21.71M | 21.51M | 30.78M | 33.52M |
| Cash, Cash Equivalents and Short-Term Investments | 6.52M | 6.52M | 9.23M | 7.81M | 15.39M | 5.00M |
| Total Debt | 376.19K | 376.19K | 776.54K | 730.71K | 998.69K | 1.26M |
| Total Liabilities | 1.74M | 1.74M | 1.72M | 1.89M | 2.49M | 4.46M |
| Stockholders Equity | 16.71M | 16.71M | 19.99M | 19.62M | 28.29M | 29.06M |
Cash Flow | ||||||
| Free Cash Flow | -4.77M | -4.77M | -4.50M | -7.32M | -6.47M | -6.05M |
| Operating Cash Flow | -4.66M | -4.66M | -4.32M | -7.02M | -6.06M | -5.26M |
| Investing Cash Flow | -104.00K | -104.00K | -174.34K | -292.27K | -411.90K | 2.64M |
| Financing Cash Flow | 2.05M | 2.05M | 5.91M | -267.98K | 16.87M | 286.48K |
Inoviq Ltd Technical Analysis
Inoviq Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$169.25M | ― | -111.23% | ― | 12.96% | 40.81% | |
48 Neutral | AU$34.21M | -4.70 | -97.79% | ― | ― | 23.85% | |
44 Neutral | AU$27.68M | -6.59 | -501.54% | ― | ― | 56.42% | |
41 Neutral | AU$60.19M | -2.93 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$49.96M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
Inoviq Ltd Corporate Events
INOVIQ Ltd held its 2025 Annual General Meeting where all resolutions were passed by poll, reflecting strong shareholder support. This outcome is significant for the company’s strategic direction and may positively influence its market positioning in the cancer diagnostics and therapeutics industry.
INOVIQ Ltd announced that Chairman David Williams will step down by year-end or upon the appointment of a new Chair, following the completion of a recent capital raising and the addition of a new Chinese cornerstone investor. Under Williams’ leadership, INOVIQ transitioned key programs from research to development, advanced its ovarian cancer test, and expanded commercialization of its exosome capture technology. The company is well-positioned to achieve its strategic objectives in the coming year, with a strengthened leadership team.
INOVIQ Ltd’s recent presentation highlights the company’s ongoing activities and strategic focus on exosome diagnostics and therapeutics. The announcement underscores the speculative nature of investments in the company, emphasizing that past performance is not indicative of future results, and that forward-looking statements are subject to change.
Inoviq Ltd has announced a change in the director’s interest notice, specifically regarding Max Johnston. The director has acquired 85,714 ordinary fully paid shares through participation in a Share Purchase Plan, increasing his total holdings to 890,024 shares. This change reflects the director’s continued investment in the company, potentially signaling confidence in Inoviq’s future prospects.
Inoviq Ltd has announced a new application for the quotation of 1,999,800 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to impact the company’s market presence by increasing its available securities for trading, potentially enhancing liquidity and investor interest.
INOVIQ Ltd has successfully completed its share purchase plan, raising a total of A$0.7 million, contributing to a total capital raise of A$10.2 million alongside a recent placement to institutional investors. The funds will be allocated to accelerate the clinical validation and commercialization of the EXO-OC™ ovarian cancer test and to advance the preclinical development of the exosome therapeutic program for solid tumors, potentially enhancing the company’s market position in cancer diagnostics and therapeutics.
Inoviq Ltd has announced its Annual General Meeting (AGM) will be held on Thursday, 27 November 2025, at the offices of Grant Thornton in Melbourne. Shareholders are encouraged to attend in person or participate virtually, though online attendees will not be able to vote. The meeting will address various matters, and shareholders are advised to submit proxy forms if unable to attend. The Chair has discretion over proceedings in case of technical difficulties, ensuring shareholder participation is considered.
INOVIQ Limited has announced the appointment of Peter Gunzburg as a director effective from October 20, 2025. The initial director’s interest notice reveals that Gunzburg holds significant interests in the company through various entities, including Supergun Pty Ltd, Trovex Pty Ltd, and Rivista Pty Ltd, with holdings in ordinary shares and listed options. This appointment and the disclosed interests may influence the company’s governance and strategic direction, potentially impacting shareholder value and market perception.
INOVIQ Ltd has issued 27,142,856 fully paid ordinary shares at an issue price of A$0.35 per share, utilizing its existing placement capacity. This strategic move is part of the company’s efforts to enhance its financial resources, potentially impacting its operations and industry positioning by supporting its ongoing and future projects in cancer diagnostics and therapeutics.
INOVIQ Ltd has appointed Peter Gunzburg as a Non-Executive Director, effective October 20, 2025. Gunzburg, who has extensive experience as a public company director and investor, previously served as Chairman of BARD1 Life Sciences Limited, now INOVIQ Ltd. His appointment follows a request by Tian An Medicare Limited, a key investor in INOVIQ’s recent capital raise. Gunzburg’s return is seen as a strategic move to leverage his knowledge of the company’s technology and direction, particularly as INOVIQ advances its exosome-based diagnostics and therapeutics. The company is focused on achieving key development and commercial milestones, with its EXO-OC™ test poised to become a leading solution for ovarian cancer screening.
Inoviq Ltd has announced a Share Purchase Plan (SPP) allowing eligible shareholders in Australia and New Zealand to purchase up to A$30,000 worth of shares without incurring additional transaction costs. This initiative aims to strengthen the company’s capital base by offering shares that will rank equally with existing ones, providing shareholders with the same rights and entitlements. The offer is not available to investors in the United States, and the company advises shareholders to rely on their own knowledge and seek advice if necessary before participating.
INOVIQ Limited has successfully completed the issuance of over 27 million fully paid ordinary shares to institutional and sophisticated investors. Additionally, the company has launched a Share Purchase Plan (SPP) offering existing shareholders in Australia and New Zealand the opportunity to purchase new shares at $0.35 each, aiming to raise up to $2 million. This initiative is part of INOVIQ’s strategy to enhance its financial position and support its ongoing advancements in cancer diagnostics and therapeutics.
Inoviq Ltd has announced the quotation of 27,142,856 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code IIQ. This move is part of a previously announced transaction, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with the company’s securities.
Inoviq Ltd has announced an update regarding its proposed issue of securities, confirming the date of 5 November 2025 as the Securities Purchase Plan (SPP) issue date. This update is part of the company’s ongoing efforts to manage its securities offerings and ensure compliance with the ASX Listing Rules, which may impact its market operations and stakeholder interests.
Inoviq Ltd has announced a proposed issue of securities, including a securities purchase plan and a placement, with a total of 32,857,146 ordinary fully paid securities to be issued. This move is aimed at raising capital to support the company’s operations and strategic initiatives, potentially impacting its market position and offering opportunities for stakeholders.
INOVIQ Ltd has announced a capital raise to support its ongoing development in the field of next-generation cancer diagnostics and therapeutics. This move is expected to enhance the company’s operational capabilities and strengthen its position in the competitive cancer diagnostics market, potentially benefiting stakeholders by accelerating the development of its innovative technologies.
INOVIQ Limited has successfully raised A$9.5 million through a placement to institutional and sophisticated investors, with an additional A$2 million targeted through a share purchase plan (SPP). The funds will accelerate the clinical validation and commercialization of the EXO-OC™ ovarian cancer test and the preclinical development of a therapeutic program for solid tumors. Tian An Medicare Limited, a Hong Kong-listed company, has committed A$5 million as a cornerstone investor, highlighting the strategic importance of INOVIQ’s test in improving women’s health outcomes. The investment will also facilitate the test’s commercialization in China, leveraging Tian An Medicare’s extensive healthcare network. This capital raising is expected to enhance INOVIQ’s market position and achieve key milestones for stakeholders.
Inoviq Ltd has requested a trading halt on its securities, pending an announcement regarding a proposed capital raising. This halt is expected to last until the announcement is made or until the commencement of trading on October 13, 2025. The trading halt indicates a strategic move by Inoviq Ltd to potentially strengthen its financial position, which could have implications for its market operations and investor relations.
INOVIQ Ltd has announced its Annual General Meeting (AGM) scheduled for November 27, 2025, with a deadline for director nominations set for October 9, 2025. This announcement is part of the company’s ongoing governance and operational activities, potentially impacting its strategic direction and stakeholder engagement.
INOVIQ Ltd has announced the publication of proof-of-concept data demonstrating the efficacy of its engineered CAR-T-exosomes in killing cancer cells and the scalability of its EXO-ACE manufacturing platform. The study, published in the Journal of Visualized Experiments, highlights the potential of INOVIQ’s CAR-exosome therapies to transform cancer treatment by offering a cell-free approach to target and destroy solid tumors, with potential advantages in safety, efficacy, and cost over traditional cell therapies.
INOVIQ Ltd has secured an exclusive worldwide license from UniQuest to develop and commercialize novel exosomal biomarkers for early detection of ovarian cancer. This license supports the development of INOVIQ’s EXO-OC test, which has shown high sensitivity and specificity in detecting early-stage ovarian cancer. The company plans to commercialize the test as a Laboratory Developed Test in the US, with further global expansion following regulatory approvals. This strategic move is expected to enhance INOVIQ’s market position and potentially revolutionize ovarian cancer detection, offering significant value to stakeholders.
INOVIQ Ltd announced positive results from in vitro studies of its CAR-NK-exosome therapeutic candidate, which demonstrated potent anti-tumor activity against Triple Negative Breast Cancer (TNBC) cells. The study, conducted at the Peter MacCallum Cancer Centre, showed that over 90% of TNBC cells were killed within 10 hours of treatment, highlighting the potential of CAR-NK-exosomes as a next-generation, cell-free therapy for solid tumors. These findings pave the way for further in vivo studies and clinical development, potentially impacting the company’s operations and positioning in the cancer treatment industry.
INOVIQ Ltd has released its Annual Report for 2025, highlighting its focus on next-generation diagnostics and therapeutics for cancer. The report provides a comprehensive overview of the company’s financial performance, governance, and operational strategies, which are crucial for stakeholders to understand the company’s current position and future prospects.